Mr. Arun Menawat reports

PROFOUND MEDICAL FURTHER STRENGTHENS EXECUTIVE LEADERSHIP TEAM WITH APPOINTMENT OF RICHARD FABIAN AS PRESIDENT

Profound Medical Corp. has appointed Richard Fabian as its new president, effective immediately. Mr. Fabian succeeds Mathieu Burtnyk, PhD, who has shifted to the newly created position of chief technology officer.

Mr. Fabian has an accomplished history of sales, marketing, operations, general and executive management success within the global health care industry, specifically in the medical imaging and medical device spaces. In a career spanning more than 29 years, he most recently served as chief executive officer of Fujifilm Sonosite Inc., an innovator and leader in point-of-care ultrasound. Before joining Sonosite in 2017, Mr. Fabian served in a variety of roles with Philips Healthcare, the primary health care and medical technology business segment and division of New York Stock Exchange-/AEX-listed Royal Philips. Starting in 2002 as a senior director in the cardiovascular X-ray business unit, North America, he progressed to lead in several executive roles in sales, marketing and global general management. Earlier in his career, Mr. Fabian was vice-president, sales, at Noetix Corp. (now Magnitude Angles) and VP, operations, at Steris Corp. Mr. Fabian received a bachelor of economics degree from the University of Michigan, where he was a two-time letterman on the varsity swim team and a master of business administration from the University of Pittsburgh Joseph M. Katz Graduate School of Business.

"I am excited that we were able to recruit a medical device executive of Rich's calibre to this key position," said Arun Menawat, Profound's chief executive officer and chairman. "Rich is a seasoned leader with a strong track record of delivering profitable growth to both established and emerging health care businesses. I have tremendous confidence in his ability to help us sharpen our overall execution. At the same time, I am pleased that our continuing clinical innovation and development will be in the capable hands of Mathieu, the inventor of the patented closed-loop temperature feedback control algorithm used by Tulsa-Pro, as well as the executive who has led the scientific design and execution of all of our clinical studies for the technology, including the ongoing Level 1 postmarket Captain randomized controlled trial."

"I am incredibly energized to join Profound at such a transformative time in the evolutions of both robotic and incisionless surgeries," commented Mr. Fabian. "By combining the unrivalled precision and patient-centered customization enabled by real-time MRI guidance and thermometry, artificial intelligence, and supervised autonomous robotics, Profound is truly changing the paradigm for patients facing prostate disease and other conditions -- proving that effective treatment no longer requires compromising a patient's quality of life. I am honoured to be part of a team that is actively replacing uncertainty with clarity and expanding the boundaries of modern medicine."

About Profound Medical Corp.

Profound is a commercial-stage medical device company and an innovator in interventional MRI (iMRI) procedures. The company's flagship platform, Tulsa-Pro, enables MRI-guided, incision-free prostate ablation. Physicians use the Tulsa Procedure to see, ablate and confirm therapy in real time, supporting personalized treatment strategies across the continuum of prostate care -- from whole gland to subtotal, hemi, multifocal and focal treatment. This approach enables individualized care using prostate tissue ablation, while minimizing the potential of the side effects that are typically associated with surgery or radiation, such as urinary incontinence and/or erectile dysfunction.

Profound also commercializes Sonalleve, an MRI-guided therapy that provides a non-surgical treatment option for pain palliation of bone metastases, desmoid tumours and osteoid osteoma, as well as for common gynecologic conditions including uterine fibroids and adenomyosis. Sonalleve delivers targeted therapy with no incisions, no blood loss during the procedure, no overnight hospital stay and faster recovery -- and, in gynecologic applications, enables uterine-sparing treatment that may help preserve fertility. Profound is also exploring additional clinical applications for Sonalleve, including non-invasive ablation of abdominal cancers and hyperthermia-based cancer therapies.

Profound Medical's technologies are approved across major global markets. Tulsa-Pro is cleared by the Food and Drug Administration in the United States for transurethral ultrasound ablation (Tulsa) of prostate tissue. In addition, Tulsa-Pro is cleared for use in various jurisdictions including Europe, Canada, Saudi Arabia, India, Australia/New Zealand and the United Arab Emirates. Sonalleve is approved by the FDA as HDE in the United States for the treatment of osteoid osteomas in the extremities. Sonalleve is also cleared or approved in the Europe, Canada, China and Saudi Arabia.

Through real-time MRI guidance and data-driven innovation, Profound is advancing the future of MRI-guided therapy -- expanding access to precise, personalized and incision-free treatment options worldwide.

We seek Safe Harbor.